Upamostat

Overview

Upamostat (WX-671), a prodrug of WX-UK1, is an orally active serine protease inhibitor . Upamostat inhibits the urokinase-type plasminogen activator (uPA) system, blocking the plasminogen activation process mediated by it, thereby suppressing the invasion, migration and metastasis of tumor cells. Upamostat can be used in the research of metastatic breast cancer and locally advanced pancreatic cancer .

Application

Products | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Metastatic Breast Cancer | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PAI-1 | Products > Signaling Pathways > Ser/Thr Protease

Product Information

• Catalog No.: HY-16511
• CAS No.: 590368-25-5
• Molecular Formula: C32H47N5O6S
• Molecular Weight: 629.81
• Purity: 99.02%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (3.30 mM); Clear solution
• Availability: In-stock

Source

Original product source